Business
Azitra, Inc. Announces Presentation at ASCO 2025 Highlighting Clinical Trial Investigating ATR-04 for EGFRi-Associated Rash
Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that it will present a poster describing the Phase 1/2 clinical trial of ATR04-484 in EGFR inhibitor ("EGFRi")-associated rash at the 2025 American Society of Clinical Oncology Annual Meeting (ASCO 2025) being held May 30-June 3, 2025 in Chicago.
About this update from Azitra Inc
[{"type":"text","content":"BRANFORD, Conn., May 28, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that it will present a poster describing the Phase 1/2 clinical trial of ATR04-484 in EGFR inhibitor ("EGFRi")-associated rash at the 2025 American Society of Clinical Oncology Annual Meeting (ASCO 2025) being held May 30-June 3, 2025 in Chicago.","length":467,"tagName":"p"},{"type":"image","alt":"Azitra Logo (PRNewsfoto/Azitra, Inc.)","displaySize":"","headline":null,"caption":"Azitra Logo (PRNewsfoto/Azitra, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":199,"url":"https://media.zenfs.com/en/prnewswire.com/75baaaf4bd9c14c2c8baec6d5cdef4c5"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ADn6KpXSrfB9stFJaBf9GA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTM1MTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/75baaaf4bd9c14c2c8baec6d5cdef4c5","width":400,"height":199}},"href":"https://mma.prnewswire.com/media/2555910/Azitra_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The presentation titled, "Epidermal growth factor receptor (EGFR) inhibitor-induced dermal toxicity treated with topical application of a novel Staphylococcus epidermidis compound," will highlight Azitra's multicenter, randomized, double-blind, vehicle-controlled Phase 1/2 clinical trial investigating the safety and tolerability of ATR04-484 for the treatment of EGFRi-induced dermal toxicity in adult patients. ATR04-484 is a live biotherapeutic product candidate including an isolated, naturally derived Staphylococcus epidermidis strain that was engineered to be safe by deleting an antibiotic resistance gene and engineering auxotrophy to control the growth of ATR04-484. Azitra has received Fast Track designation from the FDA for EGFRi-associated rash.","length":774,"tagName":"p"},{"type":"text","content":"Multiple cancers, including non-small cell lung cancer (NSCLC) and colorectal cancer, are treated with EGFRi therapies that work by blocking the activity of the EGFR protein, which plays a crucial role in cell growth and survival. However, EGFRis are also associated with unique dermatologic toxicities that can hamper treatment efforts and cause significant physica...